Praxbind

Idarucizumab · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for Praxbind, covering 2015-10-16 to 2026-04-23. Get the full timeline:

Most recent: EMA Authorised: Praxbind (idarucizumab) — Boehringer Ingelheim International GmbH